DYNACIRC CR Drug Patent Profile
✉ Email this page to a colleague
When do Dynacirc Cr patents expire, and what generic alternatives are available?
Dynacirc Cr is a drug marketed by Glaxosmithkline Llc and is included in one NDA.
The generic ingredient in DYNACIRC CR is isradipine. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the isradipine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dynacirc Cr
A generic version of DYNACIRC CR was approved as isradipine by WATSON LABS TEVA on January 5th, 2006.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DYNACIRC CR?
- What are the global sales for DYNACIRC CR?
- What is Average Wholesale Price for DYNACIRC CR?
Summary for DYNACIRC CR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 119 |
Clinical Trials: | 3 |
Patent Applications: | 5,704 |
DailyMed Link: | DYNACIRC CR at DailyMed |
Recent Clinical Trials for DYNACIRC CR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Texas at Austin | Early Phase 1 |
National Institute on Drug Abuse (NIDA) | Early Phase 1 |
Northwestern University | Phase 2 |
US Patents and Regulatory Information for DYNACIRC CR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline Llc | DYNACIRC CR | isradipine | TABLET, EXTENDED RELEASE;ORAL | 020336-001 | Jun 1, 1994 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Glaxosmithkline Llc | DYNACIRC CR | isradipine | TABLET, EXTENDED RELEASE;ORAL | 020336-002 | Jun 1, 1994 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DYNACIRC CR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxosmithkline Llc | DYNACIRC CR | isradipine | TABLET, EXTENDED RELEASE;ORAL | 020336-002 | Jun 1, 1994 | ⤷ Sign Up | ⤷ Sign Up |
Glaxosmithkline Llc | DYNACIRC CR | isradipine | TABLET, EXTENDED RELEASE;ORAL | 020336-001 | Jun 1, 1994 | ⤷ Sign Up | ⤷ Sign Up |
Glaxosmithkline Llc | DYNACIRC CR | isradipine | TABLET, EXTENDED RELEASE;ORAL | 020336-002 | Jun 1, 1994 | ⤷ Sign Up | ⤷ Sign Up |
Glaxosmithkline Llc | DYNACIRC CR | isradipine | TABLET, EXTENDED RELEASE;ORAL | 020336-002 | Jun 1, 1994 | ⤷ Sign Up | ⤷ Sign Up |
Glaxosmithkline Llc | DYNACIRC CR | isradipine | TABLET, EXTENDED RELEASE;ORAL | 020336-001 | Jun 1, 1994 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DYNACIRC CR
See the table below for patents covering DYNACIRC CR around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Belgium | 898819 | ⤷ Sign Up | |
Finland | 781867 | ⤷ Sign Up | |
Japan | H0369910 | ⤷ Sign Up | |
Netherlands | 193066 | ⤷ Sign Up | |
Norway | 884259 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |